For instance, EGFR is overexpressed in over 60% of non-small-cell lung carcinoma (NSCLC)5,6, with mutation rates ranging from 7% to 67% in NSCLC adenocarcinoma patients globally.7 Here, EGFR is linked to non-small cell lung carcinoma.